Post-Vioxx era puts pressure on Merck
59069
NEW YORK - The stunning news Thursday that Merck &amp; Co. is withdrawing its pain reliever Vioxx from the market because of health risks is the latest in a series of blows to what only a few years ago was the
597746
Industry analysts are predicting US regulators this month will refuse to approve Merck &amp; Co.&#39;s new arthritis drug until at least 2006 because of heart attacks linked to its recalled sister drug Vioxx.
574875
NEW YORK - Merck suffered a huge blow last week when it had to pull its blockbuster painkiller Vioxx from the market after a big study showed that it doubled the risk of heart attacks and strokes.
206148
Merck reduced its 2004 forecast by 50 cents to 55 cents because of lost revenues. The move followed the recall of Vioxx from the global market on September 30th, due to its association with increased risk of heart attacks.
704632
NEW YORK, Sept. 30 -- Wall Street closed out a dismal third quarter with a mixed performance Thursday after Merck said it would be forced to remove its best-selling Vioxx arthritis drug from the market. Merck's unexpected bad news left blue chips with a loss for the day, while high-tech stocks got a lift from bargain hunters.
313849
Merck &amp; Co., under siege because of lost revenues from its recalled blockbuster arthritis drug Vioxx, will cut about 5,100 jobs by year&#39;s end, more than originally planned, and will slash hundreds of millions of dollars in spending, Chairman Raymond V
350800
NEW YORK, Nov. 11 -- The 40 percent share price slide in Merck &#38; Co. in the five weeks after it pulled the painkiller Vioxx off the market highlighted larger problems in the pharmaceutical industry that may depress performance for years, according to academics and stock analysts who follow the sector.
81161
Drug giant Merck pulled its painkiller Vioxx because it increased the risk of heart attacks and strokes. Now the company may face thousands of lawsuits.
764330
U.S. stock futures pointed to a  slightly lower open on Tuesday as investors take a step back  after last week's three-day rally, with shares of drug maker  Merck & Co. MRK.N under pressure as regulators step up  investigations into the company's withdrawal of its pain  reliever, Vioxx.
339141
Merck can&#39;t expect any immediate relief from the medicine that was supposed to replace Vioxx, the pain medication it took off the market.
750945
Its products have relieved pain and suffering, and prolonged life for hundreds of millions of consumers. If you&#39;ve been following the Vioxx &quot;scandal,&quot; Merck is now in the cross-hairs of plaintiffs&#39; attorneys, politicians and certain elements of the FDA.
298813
Merck &amp; Co.'s decision to pull its widely prescribed drug Vioxx off the shelves yesterday because of a risk of stroke and heart attacks marked a new low for a pharmaceutical company that has suffered a steady decline in both market position and prestige over the last decade.
39444
In June 1998, Merck was falling behind in a high-stakes race to get Vioxx on the market ahead of its rivals, and Edward Scolnick, the company&#39;s chief scientist, was showing the strain.
636013
Pharma company weathered a tough year but should ride out its Vioxx troubles.
515664
Pharmaceutical giant Merck &amp; Co., under siege over revenues lost since it recalled arthritis drug Vioxx, will have cut about 5,100 jobs by year&#39;s end, 700 more than first planned, and will slash costs by $2.4 billion over four years, chairman and CEO
695440
Now that Merck has removed its arthritis painkiller Vioxx from the market after tests found it increased the risk of heart attacks and strokes, its rival Pfizer is taking a surprising stance.
577197
Internal e-mails at US drug maker Merck show as long as four years ago the company saw a link between Vioxx and increased heart risk.